Document is current
Any future updates will be listed below
-
Authors
Li, Wenpan https://orcid.org/0000-0002-8546-7384
Wang, Zhiren
Li, Mengwen
Jiang, Yanhao https://orcid.org/0009-0006-2403-0601
Wu, Shuang
Cordova, Leyla https://orcid.org/0009-0009-3992-7157
Kim, MinHyeok https://orcid.org/0009-0007-0766-3869
Lu, Jianqin https://orcid.org/0000-0002-5877-619X
-
Funding
Funding for this research was provided by:
Pharmaceutical Research and Manufacturers of America Foundation (Faculty Starter Grant in Drug delivery)
Foundation for the National Institutes of Health (R35GM147002)
Foundation for the National Institutes of Health (R01CA272487)
Startup and Retention Funds from the R. Ken Coit College of Pharmacy at The University of Arizona (UArizona); UArizona Comprehensive Cancer Center (UACCC) Internal Pilot and Within Reach Awards
- License Information
-
More Information
Article History
Received: 16 May 2025
Accepted: 17 April 2026
First Online: 28 April 2026
Competing interests
: J.L. has applied for patents related to Sphingomyelin-derived drug nanotechnology. The other authors have no competing interests.
